LCAP for ANCA-associated vasculitis presenting with rapidly progressive glomerulonephritis

LCAP for ANCA-associated vasculitis presenting with rapidly progressive glomerulonephritis - LCAP for AAV

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010944

Enrollment

Registered

2013-06-13

Start date

2013-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ANCA-associated vasculitis

Interventions

5 times of LCAP (two times for one week)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. new onset of AAV and 2. RPGN

Exclusion criteria

Exclusion criteria: 1. WBC and Plt counts lower than 3000/mm3 and 100,000/mm3, respectively 2. history of allergic reaction to FOY 3. severe cardiovascular, liver, lung, metabolic, neurologic or infectious diseases 4. prescription of ACEI 5. recent history of plasmapheresis

Design outcomes

Primary

Measure	Time frame
1. improvement of serum creatinine 2. life survival at 6 months after treatment	—

Secondary

Measure	Time frame
1. improvement of CRP 2. life survival at one month after treatment 3. renal prognosis 4. change of GFR 5. improvement of lung lesion 6. occurrence of infection 7. a kind and frequency of sode effects	—

Countries

Japan

Contacts

Public ContactShouichi Fujimoto

University of Miyazaki Department of Hemovascular Medicine and Artificial Organs

fujimos@med.miyazaki-u.ac.jp0985859761

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026